Global (United States, European Union and China) LATAM Adalimumab Market Research Report 2019-2025

Global (United States, European Union and China) LATAM Adalimumab Market Research Report 2019-2025

  • QYResearch
  • August 2019
  • Pharmaceutical
  • 117 pages

Report Description

Adalimumab was first approved in the U.S. for the treatment of aforementioned medical conditions. Currently, this is marketed in more than 60 countries. However, owing to the biologic nature of the drug, it results in high cost and low accessibility in emerging economies such as LATAM and Asia Pacific. On the other hand, with the probable entry of the adalimumab biosimilars post the patent expiry the low costs up to less than 25% to 35% of the originator drugs will boost the uptake and prescription of adalimumab for the treatment of above mentioned medical conditions.
Consistent technological sophistications in development of biosimilar followed by increasing incidence and prevalence of various medical conditions have rendered encouraging growth opportunities for various biological drugs and other innovative biopharmaceuticals. The LATAM adalimumab market by application has been categorized on the basis of the usage of adalimumab for treatment of various medical conditions.
In 2019, the market size of LATAM Adalimumab is xx million US$ and it will reach xx million US$ in 2025, growing at a CAGR of xx% from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for LATAM Adalimumab.

This report studies the global market size of LATAM Adalimumab, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
This study presents the LATAM Adalimumab sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.

In global market, the following companies are covered:
AbbVie, Inc.
Amgen, Inc.
Boehringer Ingelheim GmbH
Eisai Co., Ltd.
Mylan N.V.
Novartis AG
Pfizer, Inc.

Market Segment by Product Type
Oral Type
Injection Type

Market Segment by Application
Rheumatoid Arthritis
Crohns Disease
Ulcerative Colitis

Key Regions split in this report: breakdown data for each region.
United States
European Union
Rest of World (Japan, Korea, India and Southeast Asia)

The study objectives are:
To analyze and research the LATAM Adalimumab status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
To present the key LATAM Adalimumab manufacturers, presenting the sales, revenue, market share, and recent development for key players.
To split the breakdown data by regions, type, companies and applications
To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
To identify significant trends, drivers, influence factors in global and regions
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market

In this study, the years considered to estimate the market size of LATAM Adalimumab are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025

Have query on this report?

Make an Enquiry
Table of Contents
1 Report Overview
1.1 Study Scope
1.2 Major Manufacturers Covered in This Report
1.3 Market Segment by Type
List of Tables and Figures
Figure LATAM Adalimumab Product Picture
Table LATAM Adalimumab Key Market Segments
Table Major Manufacturers LATAM Adalimumab Covered in This Report
Table Global LATAM Adalimumab Market Size Growth Rate by Type 2019-2025 (K Units) & (Million US$)
Figure Global LATAM Adalimumab Sales Market Shar by Type 2014-2025

Success Stories

Our Clients

Tell Us What You Need and We’ll Get Back with the Best Solutions Available.


get in touch

Location :

State Tower, 90 State Street, Suite 700, Albany NY - 12207, United States

Call Us :

US/Canada toll free : 866-997-4948

Tel : +1-518-621-2074